How Repurposed Drugs Are Changing the Way We Think About Cancer Metabolism

Est. Reading Time: 5 Minutes

For decades, cancer therapy has followed a familiar pattern… cut, poison, burn. Surgery, chemotherapy, and radiation remain the backbone of oncology. But beneath that conventional surface, a quiet revolution is underway, one that targets the metabolism of cancer cells rather than their DNA.

And surprisingly, the tools leading this revolution aren’t new designer drugs. They’re old, inexpensive medications with a new purpose.

Rethinking the Battlefield: Metabolism, Not Just Mutations

While the genetics of cancer are complex, almost all malignancies share one universal trait: metabolic reprogramming. Cancer cells shift away from efficient mitochondrial respiration toward a primitive, glucose-hungry mode of energy production known as the Warburg effect (1). This metabolic detour fuels rapid growth but also exposes vulnerabilities.

Modern research into this effect shows that this metabolic shift is not just a symptom of cancer but a functional driver of tumor survival, immune evasion, and resistance to therapy (1).

If we can normalize that dysfunctional metabolism through nutrition, lifestyle, or specific metabolic regulators, we can change the terrain in which cancer grows.

That’s where repurposed drugs enter the picture.

Metformin: Calming the Metabolic Storm

Originally developed for diabetes, metformin has quietly become one of the most studied metabolic modulators in oncology.

By activating the AMPK pathway and dampening mTOR signaling, metformin decreases insulin levels and growth factor signaling that fuel malignant proliferation. Beyond that, it also reduces levels of inflammatory cytokines, improves mitochondrial quality control, and enhances antitumor immunity, all of which reinforce its anticancer potential (2).

All of this together effectively re-educates the body’s metabolism after cancer treatment.

Clinical evidence continues to show improved treatment responses across several cancers, even in non-diabetic patients (3,4). Population studies consistently show lower cancer incidence and mortality among metformin users (3,4).

In the R-MOP framework, metformin often serves as the metabolic backbone, stabilizing glucose levels, reducing inflammation, and improving energy balance.

Statins: Beyond Cholesterol

Statins are best known for lowering cholesterol, but their influence extends deep into cellular metabolism. They inhibit the mevalonate pathway, reducing the availability of lipids and isoprenoids that are critical for cell membrane formation and signaling.

Because many oncogenic proteins depend on mevalonate-derived intermediates, statins can weaken signaling networks that cancers rely on for survival and metastasis (5). Interrupting this pathway essentially reduces the cancer’s aggressiveness. Statins can also lower systemic inflammation, a key driver of both recurrence and comorbidity. 

On top of this, emerging evidence supports that statins may impair cancer stem cell renewal and enhance the effectiveness of other metabolic therapies (6). In fact, when used judiciously, they complement metformin by targeting a different branch of metabolic regulation.

This synergistic effect among repurposed drugs continues to show great promise in research and clinical settings.

Doxycycline: Targeting Mitochondrial Overdrive

Doxycycline is an antibiotic, but it also inhibits mitochondrial biogenesis in abnormal or stem-like cancer cells. Cancer stem cells rely heavily on newly formed mitochondria to sustain growth; doxycycline interferes with that process, selectively weakening them (7). It does this by inhibiting mitochondrial ribosomes, forcing cancer cells into an energetic crisis, making them more susceptible to additional metabolic stressors (7). 

In metabolic remission care, short cycles of doxycycline can help “reset” mitochondrial dynamics while its anti-inflammatory effects assist tissue recovery. This mitochondrial pressure reduces cancer stem cell viability and can increase sensitivity to chemotherapy and other targeting agents (8).

Mebendazole: Disrupting the Architecture of Growth

Once prescribed for intestinal worms, mebendazole destabilizes microtubules, the structural scaffolds of cell division, and also interferes with mitochondrial energy metabolism (9). By collapsing the microtubule network, mebendazole disrupts not only cell division but also intracellular transport and metabolic routing, placing cancer cells under structural and energetic constraints (9). 

One of the best things: it selectively stresses cancer cells while leaving healthy cells largely unaffected. In survivorship protocols, it’s often used in low, pulsed dosing to minimize toxicity while maintaining metabolic pressure on dormant or slow-cycling cells.

Case studies and reviews report promising activity across glioblastoma, melanoma, lung cancer, and colorectal cancer, supporting its potential role in combination approaches (10, 11).

Adjunct Agents: Ivermectin and Low-Dose Naltrexone (LDN)

Two additional repurposed agents have gained attention for complementary roles:

  • Ivermectin: Preclinical studies show that ivermectin exerts broad antitumor effects: inhibiting proliferation, metastasis, and angiogenesis across multiple cancer types by regulating signaling pathways such as PAK1, MAPK, Wnt/β-catenin, PI3K/Akt/mTOR, and STAT3. Promoting forms of programmed cell death (apoptosis, autophagy, and pyroptosis) and has shown activity against cancer stem cells and multidrug-resistance phenotypes. (12)
  • LDN (low-dose naltrexone): Review evidence indicates that LDN acts as an adjuvant in anticancer therapy by intermittently blocking the OGFr, thereby inducing a compensatory increase in OGF, which then exerts inhibitory control on cancer cell proliferation and survival. LDN also modulates the immune microenvironment; it can regulate cytokine levels, enhance NK and CD8+ T-cell responses, and reduce immune-suppressive signals in the tumor niche. (13)

These are individualized tools, not universal prescriptions, but they exemplify the expanding potential of repurposed pharmacology in metabolic care.

Synergy Through Metabolic Weakness

Cancer metabolism is a web, not a single pathway. When you disrupt glucose signaling (metformin), cancer cells compensate by increasing mitochondrial lipid synthesis. When you block the mevalonate pathway (statins), cancer cells shift toward glycolysis or glutamine. When you inhibit mitochondrial biogenesis (doxycycline), they become more dependent on microtubules and nutrient uptake, making them more vulnerable to mebendazole. 

While all of these together will not likely be prescribed to one patient, this illustrates the idea of a multi-point disruption creating metabolic cornering: pressure from different angles that cancer cells cannot adapt to simultaneously.  

What can happen when two individually survivable stresses come together and make a lethal combination is what scientists call “synthetic lethality” (14). Cancer cells, already burdened by mutations and metabolic strain, are especially vulnerable to this. 

Repurposed drugs exploit this by stacking metabolic disruptions, and when combining any of these with traditional treatments like chemotherapy or radiation, you have a dual-strike alliance. While any single stress may be manageable, the combination overwhelms cancer cells’ limited flexibility, aligning with modern synthetic lethality research (14).

Why Repurposing Matters

Repurposed drugs are attractive not just for their mechanisms, but for their practical advantages:

  • Long-term safety data and known side-effect profiles
  • Low cost and wide availability
  • Ability to combine synergistically in low doses
  • Rapid translation from bench to bedside without new FDA approval cycles

They allow clinicians to practice evidence-guided innovation within ethical, transparent frameworks, something traditional drug pipelines rarely permit.

The Integrative Future: Terrain-Based Oncology

In the Remission Metabolic Optimization Protocol (R-MOP) at Meakin Metabolic Care, these repurposed medications are integrated with lifestyle, nutritional, and supplement strategies to create a comprehensive metabolic rehabilitation plan.

The aim is not only to suppress malignant behavior but to systemically restore metabolic balance, mitochondrial health, hormonal stability, and immune competence. It’s a shift from attacking disease to re-engineering biology. Instead of waiting for recurrence, we stabilize the terrain, reducing the signals cancer depends on to thrive.

A Paradigm Shift in Motion

The story of repurposed drugs in oncology is still being written, but its message is clear: Healing cancer isn’t only about removing what’s wrong, it’s about restoring what’s right.

By applying proven, well-understood medicines in innovative ways, we can bridge the gap between conventional care and the emerging science of metabolic optimization.

The future of oncology will not be defined by new drugs alone, but by new ways of using the ones we already have.

To learn how R-MOP can help you move from recovery to optimization, visit our Remission page.

Sources


  1. https://www.science.org/doi/10.1126/science.123.3191.309
  2. https://pubmed.ncbi.nlm.nih.gov/24985407/
  3. https://www.nature.com/articles/s41416-023-02204-2
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6497052/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC10417177/
  6. https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02041-2
  7. https://www.oncotarget.com/article/3174/text/
  8. https://www.oncotarget.com/article/18428/text/
  9. https://www.oncotarget.com/article/14990/text/
  10. https://ecancer.org/en/journal/article/443-repurposing-drugs-in-oncology-redo-mebendazole-as-an-anti-cancer-agent
  11. https://www.pccarx.com/Blog/exploring-the-oncology-potential-of-mebendazole-and-ivermectin-what-compounding-pharmacists-should-know?utm_source=chatgpt.com
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10968813/
  14. https://www.nature.com/articles/s41467-021-21544-2

Related Categories: R-MOP

Disclaimer: This article is for educational purposes only and is not medical advice. Always consult your clinician before making any medical or medication decisions.